Yingcai Feng

发表

Title : Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages

JinYu, Y. Wan, C. Shu, 2018 .

699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

X. Liu, Xiaomin Song, Tong Zhang, 2020, Journal for ImmunoTherapy of Cancer.

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

J. Ji, Xiaoxiao Hu, S. Cheung, 2015, Molecular Cancer Therapeutics.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.

Structural basis for activation and inhibition of the secreted chlamydia protease CPAF.

J. Chai, Ding Chen, G. Zhong, 2008, Cell host & microbe.

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

Xiaomin Song, Tong Zhang, Yucheng Li, 2021, FEBS open bio.

Structural insights into host GTPase isoform selection by a family of bacterial GEF mimics

J. Chai, R. Orchard, N. Alto, 2009, Nature Structural &Molecular Biology.

Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab

X. Liu, Hanzi Sun, Yuan Hong, 2019, Immunology.